Trump's Drug Price Promise: Did it Knock a Pharma Rep Off Their Feet? (Watch)

**Pharma Executive Collapses During Trump's Drug Price Cut Announcement**

Trump's Drug Price Promise: Did it Knock a Pharma ...

Washington D.C. – A dramatic scene unfolded in the Oval Office on Thursday as a pharmaceutical industry representative collapsed behind President Donald Trump during an announcement detailing a new deal aimed at lowering the cost of weight-loss medications. The incident occurred as Trump unveiled the "TrumpRx" initiative, a government website slated to launch next year, designed to broaden access to popular obesity drugs like Ozempic, Wegovy, and Zepbound.

The individual, initially misidentified as Novo

The individual, initially misidentified as Novo Nordisk executive Gordon Finlay, appeared to lose consciousness, his knees buckling while standing behind the president. Novo Nordisk, the manufacturer of Ozempic, Rybelsus, and Wegovy, later refuted claims that the man was Finlay.

Fox News reporter Jacqui Heinrich, who witnessed the event, reported that Dr. Mehmet Oz, the administrator of the Centers for Medicare and Medicaid Services, swiftly intervened, ensuring the executive did not hit his head during the fall. Following the incident, reporters were escorted out of the Oval Office as cabinet members attended to the fallen man, reportedly elevating his legs.

White House Press Secretary Karoline Leavitt later assured the press that the "gentleman is okay." The cause of the collapse remains unknown.

The incident occurred against the backdrop

The incident occurred against the backdrop of Trump's announcement of significant price reductions for weight loss drugs, particularly GLP-1 medications like Ozempic. The TrumpRx initiative promises to make these medications more affordable, with oral versions potentially starting at $149 per month upon FDA approval. Injectable GLP-1 drugs will reportedly cost $245 per month for Medicare and Medicaid patients using them for approved conditions such as diabetes.

The press conference featured executives from Novo Nordisk and Eli Lilly, both companies collaborating with the administration on the deal. The goal is to expand access to these medications, addressing the growing obesity epidemic and the financial burden it places on individuals and the healthcare system.

While the collapse added an unexpected layer of drama to the announcement, the focus remains on the potential impact of TrumpRx on the affordability and accessibility of weight-loss drugs. The initiative represents a significant step towards addressing the high cost of these medications, a concern that has been voiced by patients and healthcare advocates alike. The launch of TrumpRx next year will be closely watched to assess its effectiveness in achieving its stated goals.